2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Abstract Number: 1663

G Protein Signaling Modulator 3 Is a Key Regulator of Monocyte-Driven Inflammatory Arthritis
Abstract Number: 1133

Gait Differences Are Present in Subjects with Symptomatic Vs. Asymptomatic Mild Radiographic Hip Osteoarthritis
Abstract Number: 1176

Galactosylation, and Not Sialylation, of Immunoglobulin G Is Associated with Improvement of Rheumatoid Arthritis During Pregnancy
Abstract Number: 319

Gamma Interferon-Induced Protein-10 (IP-10) As a Potential Biomarker for Disease Activity in Pediatric Localized Scleroderma
Abstract Number: 687

Gammadelta T Cells and Their Intracellular Cytokine Profile in Peripheral Blood of Patients with Systemic Lupus Erythematosus
Abstract Number: 1747

Gemin5 Is a New Target of Autoantibodies That Are Produced in Tight Connection with Antibodies to Snrnps and Survival of Motor Neuron (SMN) Complex
Abstract Number: 1356

Gender Differences Among Spondylitis Associated with Psoriasis, Inflammatory Bowel Disease and Primary Ankylosing Spondylitis
Abstract Number: 1714

Gender Differences in Systemic Sclerosis: Relationship to Disease Specific Clinical Manifestations and Estradiol Levels
Abstract Number: 2627

Gender Differences of Concepts Important to People Living with Crohn’s Disease and Their Coverage by Commonly Used Patient-Reported Outcome Instruments: Patient’s Perspective Elevated by a Qualitative Study
Abstract Number: 1478

Gender-Associated Differences in Disease Characteristics and Outcome in Systemic Sclerosis
Abstract Number: 1315

Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis
Abstract Number: 525

Gene Expression Profiling in a Large Cohort of Europeans with Sjögren’s Syndrome Reveals Candidate Genes in Viral, Immune, and Interferon-Related Pathways
Abstract Number: 2272

Gene Expression Signatures in Monocytes From Primary Antiphospholipd Syndrome, Systemic Lupus Erythematosus and Lupus with Antiphospholipid Syndrome Identify Specific Pathways Involved in the Pathogenesis of Atherosclerosis and Cardiovascular Disease
Abstract Number: 1600

Gene Targeting of an Integrin-Mediated Signaling Adaptor Molecule, Crk-Associated Substrate Lymphocyte Type Reduced the Severity of Collagen-Induced Arthritis. Its Possible Involvement in the Pathophysiology of Rheumatoid Arthritis
Abstract Number: 2316

Generation of CD4⁺ Follicular Helper Tcells by Complement and Immune Complexes
Abstract Number: 1061

Generation of Myeloid-Derived Suppressor Cells in Vitro From Murine Bone Marrow Precursors
Abstract Number: 2274

Genes Associated with Systemic Lupus Erythematosus Show Evidence of Selection in the Gullah African American Population
Abstract Number: 520

Genetic Associations to Germinal Centre Formation in Primary Sjögren’s Syndrome
Abstract Number: 1535

Genetic Background of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Japanese Population: Association of STAT4 with Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Positive Vasculitis
Abstract Number: 995

Genetic Effects of HLA-DRB1, IL4R, and FcγRIIb On Long-Term Treatment Responses in Patients with Early Rheumatoid Arthritis: 78-Week Results of a Phase 4 Study
Abstract Number: 970

Genetic Interactions Between SNP Variants in C3 Receptor Subunits in Patients with SLE
Abstract Number: 2279

Genetic Markers for Circulating Vitamin D and the Associations with Risk of Systemic Lupus Erythematosus
Abstract Number: 1218

Genetic Markers of Functional Stress Response in Patients with Rheumatoid Arthritis
Abstract Number: 996

Genetic Predictors of Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results From the Treatment of Early Aggressive Rheumatoid Arthritis Trial
Abstract Number: 894

Genetic Variants in the IL-4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts
Abstract Number: 982

Genetic Variants near Insulin-Like Growth Factor Binding Protein 3 (IGFBP3) Are Associated with Hip Osteoarthritis
Abstract Number: 1630

Genetic Variants of Serum Uric Acid and Gout: An Analysis of > 170,000 Individuals
Abstract Number: 1386

Genetic Variation and Coronary Atherosclerosis in Patients with Systemic Lupus Erythematosus
Abstract Number: 522

Genetic Variation in the NCR3 Locus Is Associated with Anti-SSA⁄SSB Positive Primary Sjögren′s Syndrome in Scandinavian Samples
Abstract Number: 433

Genome Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with Anti-TNF Medication. Results of the DREAM and Danbio Registries
Abstract Number: 986

Genome Wide Association Studies of Knee Osteoarthritis in 2 Large North American Cohorts: A Meta-Analysis with 2667 Cases
Abstract Number: 989

Genome-Wide Analysis Reveals a Recessive Association of ERAP1 Variants with Behçet’s Disease and Epistasis Between ERAP1 and HLA-B*51
Abstract Number: 2672

Genome-Wide Association Analysis Reveals Genetic Heterogeneity of Sjögren’s Syndrome (SS) According to Specific Subphenotypes and Ancestry
Abstract Number: 2657

Genome-Wide Association Meta-Analysis of Eight Independent Systemic Juvenile Idiopathic Arthritis Collections Reveals Regional Association Spanning the Major Histocompatibility Complex Class II and III Gene Cluster
Abstract Number: 983

Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 As a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis
Abstract Number: 2654

Genome-Wide Association Study of Methotrexate Response Identifies Novel Genes in a Large Cohort of European Juvenile Idiopathic Arthritis Cases
Abstract Number: 2670

Genome-Wide Association Study On the Severity of Joint Destruction in Autoantibody Positive Rheumatoid Arthritis Identifies a Role for Sperm Associated Antigen 16
Abstract Number: 1595

Genome-Wide Association Study to High -Throughput Cell-Based Phenotypic Screen Identifies Novel Chemical Inhibitors of CD40 Signaling
Abstract Number: 2267

Genome-Wide Pathway Analysis of Genome-Wide Association Studies On Systemic Lupus Erythematosus
Abstract Number: 980

Genomewide Association Study in Systemic Lupus Erythematosus: Known Loci
Abstract Number: 1874

Genomic Categories of Fatigue in Women with Fibromyalgia
Abstract Number: 2384

Giant Cell Arteritis and Cardiovascular Events in the French Apogee Cohort. A Population-Based Study Using the French Health Insurance System Database
Abstract Number: 2548

Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients
Abstract Number: 816

Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Abstract Number: 1241

Glucocorticoid use Is associated with increase in HDL in Rheumatoid Arthritis Patients
Abstract Number: 321

Glycosylation of Vitamin D Binding Protein Reduced in Juvenile Idiopathic Arthritis Patients At Risk of Disease Extension
Abstract Number: 1366

Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo – Controlled Study
Abstract Number: 497

Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Abstract Number: 1167

Golimumab in 25 Young Adults Affected by Juvenile Idiopathic ARTHRITIS NON Responders to OTHER Biological Agents: Preliminary DATA
Abstract Number: 1324

Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks As Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy: Week 104 Results of Clinical, Radiographic and Safety Assessments
Abstract Number: 1206

Gp96 Exacerbate the Inflammation of Rheumatoid Arthritis
Abstract Number: 822

Greater Than Expected Increased Mortality Following Fragility Fractures in Women and Men with Rheumatoid Arthritis
Abstract Number: 2073

Green Tea Epigallocatechin-3-Gallate Ameliorates Murine Arthritis by Inducing IDO Producing Dendritic Cells Via Nrf2 Antioxidant Pathway
Abstract Number: 2643

Grey Matter Decrease in Fibromyalgia Is Related to Pain Catastrophizing and Pain Sensitivity
Abstract Number: 122

Grey-Scale Ultrasonography with Power Doppler Technique: An Available Tool for the Assessment of Subclinical Joint Inflammatory Activity in Juvenile Idiopathic Arthritis
Abstract Number: 1244

Group Cycling in Rheumatoid Arthritis: Positive Effects On Aerobic Capacity and Blood Pressure

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].